Market By Type, Application, Technology And Geography | Forecast 2019-2027
According to Triton, the global DNA vaccines market is expected to display a positive market trend over the forecast period of 2019-2027, exhibiting a CAGR of 42.03%. The market was assessed to be worth $1586.01 million in the year 2018 and is predicted to generate a revenue of approximately $37384.45 million by the year 2027.
DNA vaccination is necessary for gaining protection against various chronic and communicable diseases, which is carried out by introducing the genetically engineered nucleic acids in the form of DNA that triggers the cells to directly release the required antigen for specific immune response necessary for fighting the disease. DNA vaccines have multiple prospective advantages over the traditional vaccines, for instance, their wide range of immune responses.
We provide additional customization based on your specific requirements. Request For Customization
DNA vaccines are known to be the third generation vaccines. They are nucleic acids that code for specific proteins or antigens, which are isolated from a pathogen. The vaccines are made to target the cells as their base site, whose internal mechanism rests on the DNA vaccine to synthesize the necessary proteins. As these proteins are identified to be foreign, when the host cells administer these antigens/proteins, the immune system triggers the required immune responses upon receiving the alert.
DNA vaccines have many advantages, for instance, the minimal infection risk, create a rift in the T-cell response into the type 1 or type 2, immune response is customized as per the antigen of interest, easier development and production of the vaccines, ease for storage and shipping, etc.
Rapid growth is estimated in the global DNA vaccines market once these vaccines get approval for clinical trials and processing a large number of investors. Almost 100 clinical trials on humans are in progress for diseases ranging from HIV, cancer, Hepatitis, influenza, Zika infection and other infectious diseases. The Bill & Melinda Gates Foundation has donated around $100 million to Moderna Therapeutics to develop DNA vaccines for infectious diseases. Also, several government departments are funding private companies for developing DNA vaccines. For example, the US Department of Health and Services agreed to provide a fund of around $125 million to Moderna Therapeutics to develop a vaccine for Zika infection.
Within this report, Triton Market Research has discussed key insights regarding the industry. Also, the value chain outlook, key buying outlook, Porter’s five force analysis and regulatory framework have been studied for the DNA vaccines market in the report.
Market drivers like a surge in new vaccine development, increasing usage of DNA vaccines for animal healthcare and the rising prevalence of chronic & infectious diseases are evolving the market globally. The market is also facing restraints like the lack of legal & ethical framework and stringent government regulations.
The growing demand for gene therapy, steady vaccines that are easier to store & transport and the increasing number of clinical trials on humans are expected to leverage the market to achieve the projected growth over the forecast period. However, key challenges, such as variation in the regulatory pathway and the points of consideration regarding environmental valuation, are challenging the market growth.
To get detailed insights on segments, Request Free Sample Report
Top geographies that have been covered in the global DNA vaccines market report are:
• North America DNA vaccines: the United States and Canada
• Europe DNA vaccines: the United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe
• Asia-Pacific DNA vaccines: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand and Rest of Asia-Pacific
• Latin America DNA vaccines: Brazil, Mexico and Rest of Latin America
• The Middle East and Africa DNA vaccines: the United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East & Africa
The global DNA vaccines market has been segmented as follows:
• By type:
O Animal DNA vaccine
O Human DNA vaccine
• By application:
O Human disease
O Veterinary disease
• By technology:
O Plasmid DNA vaccines
O Plasmid DNA delivery
The companies leading the DNA vaccines market are Astellas Pharma, Inc., Dendreon Corporation (acquired by Sanpower Group), Eli Lilly and Company, Eurogentec S.A., GlaxoSmithKline, Inc., Inovio Pharmaceuticals, Inc., Madison Vaccines, Incorporated (MVI), Merck & Co., Merial Limited (acquired by Boehringer Ingelheim), Novartis AG, Sanofi, VGXI, Vical, Incorporated, Xenetic Biosciences, Inc. and Zoetis, Inc.
The company market share helps in analyzing the major companies in this market and also their hold on the market.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1.
GLOBAL DNA VACCINES MARKET - SUMMARY
2.
INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. PORTER’S FIVE FORCES OUTLOOK
2.2.1.
THREAT OF NEW ENTRANTS
2.2.2.
THREATS OF SUBSTITUTE PRODUCT
2.2.3.
BARGAINING POWER OF BUYER
2.2.4.
BARGAINING POWER OF SUPPLIER
2.2.5.
INTENSITY OF COMPETITIVE RIVALRY
2.3. VENDOR SCORECARD
2.4. VALUE CHAIN OUTLOOK
2.5. KEY INSIGHTS
2.6. REGULATORY FRAMEWORK
2.7. KEY BUYING OUTLOOK
2.8. MARKET DRIVERS
2.8.1.
SURGE IN NEW VACCINE DEVELOPMENT
2.8.2.
RISING USAGE OF DNA VACCINES FOR ANIMAL HEALTHCARE
2.8.3.
RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES
2.9. MARKET RESTRAINTS
2.9.1.
LACK OF LEGAL AND ETHICAL FRAMEWORK
2.9.2.
STRINGENT GOVERNMENT REGULATIONS
2.10.
MARKET OPPORTUNITIES
2.10.1.
GROWING DEMAND FOR GENE THERAPY
2.10.2.
STEADY VACCINES ARE EASY TO STORE AND
TRANSPORT
2.10.3.
INCREASING NUMBER OF CLINICAL TRIALS ON HUMANS
2.11.
MARKET CHALLENGES
2.11.1.
VARIATION IN THE REGULATORY PATHWAY AND THE POINTS OF CONSIDERATION
REGARDING ENVIRONMENTAL VALUATION
3.
DNA VACCINES MARKET OUTLOOK - BY TYPE
3.1. ANIMAL DNA VACCINE
3.2. HUMAN DNA VACCINE
4.
DNA VACCINES MARKET OUTLOOK - BY APPLICATION
4.1. HUMAN DISEASE
4.2. VETERINARY DISEASE
5.
DNA VACCINES MARKET OUTLOOK - BY TECHNOLOGY
5.1. PLASMID DNA VACCINES
5.2. PLASMID DNA DELIVERY
6.
DNA VACCINES MARKET OUTLOOK - BY REGION
6.1. NORTH AMERICA
6.1.1.
MARKET BY TYPE
6.1.2.
MARKET BY TECHNOLOGY
6.1.3.
MARKET BY APPLICATION
6.1.4.
COUNTRY ANALYSIS
6.1.4.1.
THE UNITED STATES
6.1.4.2.
CANADA
6.2. EUROPE
6.2.1.
MARKET BY TYPE
6.2.2.
MARKET BY TECHNOLOGY
6.2.3.
MARKET BY APPLICATION
6.2.4.
COUNTRY ANALYSIS
6.2.4.1.
THE UNITED KINGDOM
6.2.4.2.
FRANCE
6.2.4.3.
GERMANY
6.2.4.4.
SPAIN
6.2.4.5.
ITALY
6.2.4.6.
RUSSIA
6.2.4.7.
REST OF EUROPE
6.3. ASIA-PACIFIC
6.3.1.
MARKET BY TYPE
6.3.2.
MARKET BY TECHNOLOGY
6.3.3.
MARKET BY APPLICATION
6.3.4.
COUNTRY ANALYSIS
6.3.4.1.
INDIA
6.3.4.2.
CHINA
6.3.4.3.
JAPAN
6.3.4.4.
AUSTRALIA & NEW ZEALAND
6.3.4.5.
SOUTH KOREA
6.3.4.6.
ASEAN COUNTRIES
6.3.4.7.
REST OF ASIA-PACIFIC
6.4. LATIN AMERICA
6.4.1.
MARKET BY TYPE
6.4.2.
MARKET BY TECHNOLOGY
6.4.3.
MARKET BY APPLICATION
6.4.4.
COUNTRY ANALYSIS
6.4.4.1.
BRAZIL
6.4.4.2.
MEXICO
6.4.4.3.
REST OF LATIN AMERICA
6.5. MIDDLE EAST AND AFRICA
6.5.1.
MARKET BY TYPE
6.5.2.
MARKET BY TECHNOLOGY
6.5.3.
MARKET BY APPLICATION
6.5.4.
COUNTRY ANALYSIS
6.5.4.1.
SAUDI ARABIA
6.5.4.2.
TURKEY
6.5.4.3.
THE UNITED ARAB EMIRATES
6.5.4.4.
SOUTH AFRICA
6.5.4.5.
REST OF MIDDLE EAST & AFRICA
7.
COMPETITIVE LANDSCAPE
7.1. ASTELLAS PHARMA, INC.
7.2. DENDREON CORPORATION (ACQUIRED BY SANPOWER
GROUP)
7.3. ELI LILLY AND COMPANY
7.4. EUROGENTEC S.A.
7.5. GLAXOSMITHKLINE, INC.
7.6. INOVIO PHARMACEUTICALS, INC.
7.7. MADISON VACCINES INCORPORATED (MVI)
7.8. MERCK & CO.
7.9. MERIAL LIMITED (ACQUIRED BY BOEHRINGER
INGELHEIM)
7.10.
NOVARTIS AG
7.11.
SANOFI
7.12.
VGXI
7.13.
VICAL, INCORPORATED
7.14.
XENETIC BIOSCIENCES, INC.
7.15.
ZOETIS, INC.
8.
METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY
TABLE 1 GLOBAL DNA VACCINES
MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 2 INTERVENTIONS AND
PHASE OF SOME DISEASES/CONDITIONS
TABLE 3 REGULATIONS TO
FOLLOW BEFORE COMMERCIALIZATION
TABLE 4 TEMPERATURE REQUIREMENTS
IN PRESERVATION FOR VARIOUS VACCINES
TABLE 5 APPROACHES BEING
TESTED TO ENHANCE THE LOW IMMUNOGENICITY
TABLE 6 CLINICAL TRIALS ON
HUMANS INVOLVING DNA VACCINES
TABLE 7 GLOBAL DNA VACCINES
MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 8 GLOBAL DNA VACCINES
MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 9 GLOBAL DNA VACCINES
MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 10 GLOBAL DNA VACCINES
MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 11 NORTH AMERICA DNA
VACCINES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 12 NORTH AMERICA DNA
VACCINES MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA DNA
VACCINES MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 14 NORTH AMERICA DNA VACCINES
MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 15 EUROPE DNA VACCINES
MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 16 EUROPE DNA VACCINES
MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 17 EUROPE DNA VACCINES
MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 18 EUROPE DNA VACCINES
MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 19 ASIA-PACIFIC DNA
VACCINES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 20 ASIA-PACIFIC DNA
VACCINES MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 21 ASIA-PACIFIC DNA
VACCINES MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 22 ASIA-PACIFIC DNA
VACCINES MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 23 LATIN AMERICA DNA
VACCINES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 24 LATIN AMERICA DNA
VACCINES MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 25 LATIN AMERICA DNA
VACCINES MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 26 LATIN AMERICA DNA
VACCINES MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 27 MIDDLE EAST AND
AFRICA DNA VACCINES MARKET BY TYPE 2019-2027 ($ MILLION)
TABLE 28 MIDDLE EAST AND
AFRICA DNA VACCINES MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 29 MIDDLE EAST AND
AFRICA DNA VACCINES MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 30 MIDDLE EAST AND
AFRICA DNA VACCINES MARKET BY COUNTRY 2019-2027 ($ MILLION)
FIGURE 1 GLOBAL DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 2 VALUE CHAIN ANALYSES
FOR DNA VACCINE INDUSTRY
FIGURE 3 NORTH AMERICA DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 4 GLOBAL DNA VACCINES
MARKET IN VETERINARY DISEASES 2019-2027 ($ MILLION)
FIGURE 5 SHARE OF TRIALS BY
VACCINE TARGET IN 2016
FIGURE 6 SEGMENT OF CLINICAL
TRIALS OF DNA VACCINES BY CANCER MARKS IN 2016 (%)
FIGURE 7 CLINICAL TRIALS OF
GENE THERAPY
FIGURE 8 GLOBAL DNA VACCINES
MARKET IN ANIMAL DNA VACCINES 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL DNA VACCINES MARKET
IN HUMAN DNA VACCINES 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL DNA VACCINES
MARKET SHARE BY APPLICATION 2018 & 2027 (%)
FIGURE 11 GLOBAL DNA VACCINES
MARKET IN HUMAN DISEASES 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL DNA VACCINES
MARKET IN VETERINARY DISEASES 2019-2027
($ MILLION)
FIGURE 13 GLOBAL DNA VACCINES
MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL DNA VACCINES
MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2019-2027 ($ MILLION)
FIGURE 15 THE UNITED STATES DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 16 CANADA DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 17 THE UNITED KINGDOM DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 18 FRANCE DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 19 GERMANY DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 20 SPAIN DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 21 ITALY DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 22 RUSSIA DNA VACCINES MARKET 2019-2027 ($ MILLION)
FIGURE 23 REST OF EUROPE DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 24 INDIA DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 25 CHINA DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 26 JAPAN DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 27 AUSTRALIA & NEW
ZEALAND DNA VACCINES MARKET 2019-2027 ($ MILLION)
FIGURE 28 SOUTH KOREA DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 29 ASEAN COUNTRIES DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 30 REST OF ASIA-PACIFIC
DNA VACCINES MARKET 2019-2027 ($ MILLION)
FIGURE 31 BRAZIL DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 32 MEXICO DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 33 REST OF LATIN AMERICA
DNA VACCINES MARKET 2019-2027 ($ MILLION)
FIGURE 34 SAUDI ARABIA DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 35 TURKEY DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 36 THE UNITED ARAB
EMIRATES DNA VACCINES MARKET 2019-2027 ($ MILLION)
FIGURE 37 SOUTH AFRICA DNA VACCINES
MARKET 2019-2027 ($ MILLION)
FIGURE 38 REST OF MIDDLE EAST &
AFRICA DNA VACCINES MARKET 2019-2027 ($ MILLION)